Edwards Lifesciences Price to Free Cash Flow Ratio 2010-2024 | EW

Edwards Lifesciences current price to free cash flow ratio as of February 02, 2025 is 84.2.

  • Edwards Lifesciences average price to free cash flow ratio for 2024 was 129.92, a 100.83% decline from 2023.
  • Edwards Lifesciences average price to free cash flow ratio for 2023 was 64.69, a 31.62% increase from 2022.
  • Edwards Lifesciences average price to free cash flow ratio for 2022 was 49.15, a 19.76% increase from 2021.

Price to free cash flow ratio can be defined as

Edwards Lifesciences Price to Free Cash Flow Ratio 2010-2024 | EW

  • Edwards Lifesciences average price to free cash flow ratio for 2024 was 129.92, a 100.83% decline from 2023.
  • Edwards Lifesciences average price to free cash flow ratio for 2023 was 64.69, a 31.62% increase from 2022.
  • Edwards Lifesciences average price to free cash flow ratio for 2022 was 49.15, a 19.76% increase from 2021.

Price to free cash flow ratio can be defined as

Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$217.3B
Intuitive Surgical (ISRG)$204B
Alcon (ALC)$45.1B
IQVIA Holdings (IQV)$35.9B
IDEXX Laboratories (IDXX)$34.3B
DexCom (DXCM)$33.8B
Waters (WAT)$24B
STERIS (STE)$21.7B
SONOVA HOLDING (SONVY)$20.8B
Hologic (HOLX)$16.1B
Fresenius Medical Care AG KGaA (FMS)$14.6B
Globus Medical (GMED)$12.6B
Sysmex ADR (SSMXY)$12.2B
Penumbra (PEN)$10.4B
Masimo (MASI)$9.5B
Glaukos (GKOS)$8.8B
Teleflex (TFX)$8.4B
Integer Holdings (ITGR)$4.8B
Inari Medical (NARI)$4.7B
PROCEPT BioRobotics (PRCT)$3.8B
Veracyte (VCYT)$3.4B
LivaNova (LIVN)$2.8B
Nihon Kohden (NHNKY)$2.6B
Tandem Diabetes Care (TNDM)$2.4B
Elekta AB (EKTAY)$2.3B
TransMedics (TMDX)$2.2B
Integra LifeSciences Holdings (IART)$2B
Alphatec Holdings (ATEC)$1.7B
Artivion (AORT)$1.3B
RxSight (RXST)$1.3B